STOCK TITAN
  1. Home
  2. Sec-filings
  3. PBLS
  4. [Form 3] Parabilis Medicines, Inc. Initial Statement of Beneficial Ownership

Parabilis (NASDAQ: PBLS) CFO discloses multi-year stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Parabilis Medicines, Inc. Chief Financial Officer Thomas Rodolpho Kotarakos reported his existing stock option holdings in a Form 3. He holds options over 292,416 shares of common stock at an exercise price of $3.14 expiring on February 17, 2036, which are fully vested. He also holds options over 165,702 shares at $1.48 per share expiring on March 27, 2034, vesting in 48 equal monthly installments from January 1, 2024, and 48,736 shares at $4.82 per share expiring on December 18, 2031, vesting in 48 equal monthly installments from February 9, 2026. The filing reflects holdings only and does not show new purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Kotarakos Thomas Rodolpho
Role Chief Financial Officer
Type Security Shares Price Value
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
holding Stock Option (right to buy) -- -- --
Holdings After Transaction: Stock Option (right to buy) — 48,736 shares (Direct, null)
Footnotes (1)
  1. The shares subject to this option are fully vested. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from January 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.
Underlying shares (option 1) 292,416 shares Stock option at $3.14 exercise price, expires February 17, 2036
Exercise price (option 1) $3.14/share Stock option over 292,416 common shares, expires February 17, 2036
Underlying shares (option 2) 165,702 shares Stock option at $1.48 exercise price, expires March 27, 2034
Exercise price (option 2) $1.48/share Vests in 48 monthly installments from January 1, 2024
Underlying shares (option 3) 48,736 shares Stock option at $4.82 exercise price, expires December 18, 2031
Exercise price (option 3) $4.82/share Vests in 48 monthly installments from February 9, 2026
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)" for each derivative holding"
underlying security shares financial
"underlying_security_shares: "292416.0000" linked to Common Stock"
vest and become exercisable financial
"The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments"
equal monthly installments financial
"forty-eight (48) equal monthly installments commencing from January 1, 2024"
fully vested financial
"The shares subject to this option are fully vested."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Kotarakos Thomas Rodolpho
(Last)(First)(Middle)
C/O PARABILIS MEDICINES, INC.
30 ACORN PARK DRIVE, 6TH FLOOR
(Street)
CAMBRIDGE MASSACHUSETTS 02140
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026		3. Issuer Name and Ticker or Trading Symbol
Parabilis Medicines, Inc. [ PBLS ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) (1)12/18/2031Common Stock48,736$4.82D
Stock Option (right to buy) (2)03/27/2034Common Stock165,702$1.48D
Stock Option (right to buy) (3)02/17/2036Common Stock292,416$3.14D
Explanation of Responses:
1. The shares subject to this option are fully vested.
2. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from January 1, 2024, subject to the Reporting Person's continued service on each such vesting date.
3. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Teresa Jurgensen, Attorney-in-Fact06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What does Parabilis Medicines (PBLS) CFO report in this Form 3?

The CFO reports his existing stock option holdings in Parabilis Medicines. The filing lists three option grants over common stock, detailing underlying share amounts, exercise prices, expiration dates, and vesting schedules, without disclosing any new purchase, sale, or exercise activity.

How many Parabilis (PBLS) shares are covered by the CFO’s reported options?

The options cover 292,416, 165,702, and 48,736 underlying common shares. Each block is tied to a separate stock option grant with its own exercise price, expiration date, and vesting schedule, showing the scale and structure of the CFO’s equity-based compensation.

What are the exercise prices of the Parabilis (PBLS) CFO’s stock options?

The reported stock options have exercise prices of $3.14, $1.48, and $4.82 per share. Each price applies to a distinct grant, paired with different expiration dates and vesting schedules, indicating multiple option awards granted at different times and valuation levels.

When do the Parabilis (PBLS) CFO’s reported stock options expire?

The disclosed options expire on December 18, 2031, March 27, 2034, and February 17, 2036. These long-dated expirations show the options are intended as multi-year incentives, with some tranches already vested and others vesting monthly over four-year periods.

How do the Parabilis (PBLS) CFO’s options vest according to the Form 3?

One option grant is fully vested, meaning all related shares are currently exercisable. Two other grants vest in forty-eight equal monthly installments, starting January 1, 2024 and February 9, 2026, respectively, contingent on the CFO’s continued service each month.